Clinical Research Papers:
The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer
Metrics: HTML 921 views | ?
Xiangrui Meng1, Peng Lu2,*, Zhi Chu3, Qingxia Fan1
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou, People's Republic of China
2Department of Gastrointestinal Surgery, People's Hospital of Zhengzhou, Zheng Zhou, People's Republic of China
3General Hospital, Jinan Military Command, Jinan, Shandong Province, People's Republic of China
Qingxia Fan, e-mail: email@example.com
Keywords: ovarian cancer, AR, CAG, repeat, polymorphism
Received: June 17, 2015 Accepted: October 08, 2015 Published: October 20, 2015
Ovarian cancer is the main cause of death among women with gynecological malignancies. Androgen and its receptors play an important role in ovarian cancer pathogenesis. Here, We aim to evaluate the relationship between AR CAG and GGN repeat length polymorphisms and Epithelial Ovarian Cancer (EOC) risk in a two-stage, case-control study among Chinese women. The repeat length was analyzed as a categorical variable for CAG_A and GGN_A (average allele), CAG-S and GGN_S (shorter allele), CAG-L and GGN_L (longer allele), respectively. The median value of the repeat length among the controls was used as the cutoff point. Women with longer AR CAG repeats had a decreased risk of developing EOC. The results was replicated in an independent samples. Compared to those with shorter (<22) CAG_A repeat length, women with longer (≥22) CAG_A repeats length had a 31% decreased EOC risk (OR = 0.69, 95% CI: 0.62–0.77, P = 5.06 × 10−11). For CAG_S and CAG_L, the results remain consistent. However, we didn’t detected any significant associations for GGN_A, GGN_S, and GGN_L. This should be the first study to examine the association between AR repeat length polymorphisms and ovarian cancer risk in a relatively large group of Asian women.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.